<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pelvic inflammatory disease: Treatment in adults and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pelvic inflammatory disease: Treatment in adults and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pelvic inflammatory disease: Treatment in adults and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold C Wiesenfeld, MD, CM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pelvic inflammatory disease (PID) refers to acute infection of the upper genital tract structures in females, involving any or all of the uterus, fallopian tubes, and ovaries and may involve the neighboring pelvic organs. Early diagnosis and treatment are believed to be key elements in the prevention of long-term sequelae, such as infertility and ectopic pregnancy. (See  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p>The treatment of PID will be reviewed here. The pathogenesis of, risk factors for, and sequelae following PID are discussed separately. The management of tubo-ovarian abscess is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7580.html" rel="external">"Pelvic inflammatory disease: Pathogenesis, microbiology, and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/5469.html" rel="external">"Pelvic inflammatory disease: Long-term complications"</a> and  <a class="medical medical_review" href="/z/d/html/16419.html" rel="external">"Management and complications of tubo-ovarian abscess"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">MICROBIOLOGIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>Acute pelvic inflammatory disease (PID) is an ascending polymicrobial infection caused by cervical microorganisms (including <em>Chlamydia trachomatis</em> and <em>Neisseria gonorrhoeae</em>, and potentially <em>Mycoplasma genitalium</em>), as well as the vaginal microflora, including anaerobic organisms, enteric gram-negative rods, streptococci, genital mycoplasmas, and <em>Gardnerella vaginalis</em>, which is associated with bacterial vaginosis [<a href="#rid1">1</a>]. Treatment of PID generally requires broad antimicrobial coverage, particularly among those with severe disease requiring hospitalization. (See  <a class="medical medical_review" href="/z/d/html/7580.html" rel="external">"Pelvic inflammatory disease: Pathogenesis, microbiology, and risk factors", section on 'Microbiology'</a> and <a class="local">'Antibiotic selection'</a> below.) </p><p class="headingAnchor" id="H2456585734"><span class="h2">Chlamydia and gonorrhea</span><span class="headingEndMark"> — </span>PID is primarily a disease of sexually active females. The two most important sexually transmitted organisms associated with acute PID, <em>C. trachomatis</em> and <em>N. gonorrhoeae</em>, should be the main targets for treatment. Even if endocervical testing is not positive for either of these pathogens, they should still be covered, as upper tract infection cannot be ruled out [<a href="#rid2">2</a>].</p><p>Drug resistance is an ongoing challenge in the therapy of gonococcal infections. As an example, the prevalence of fluoroquinolone resistance in <em>N. gonorrhoeae</em> reaches nearly 100 percent in some regions, and these agents are no longer recommended for treatment of <em>N. gonorrhoeae</em> infections. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Antibiotic resistance'</a>.)</p><p class="headingAnchor" id="H2116945198"><span class="h2">Anaerobic bacteria</span><span class="headingEndMark"> — </span>Anaerobic bacteria, in particular organisms associated with bacterial vaginosis, are frequently recovered from the upper genital tract of females with acute PID [<a href="#rid3">3,4</a>]. Whether antibiotic therapy for PID should routinely include anaerobic coverage has been controversial [<a href="#rid2">2,5</a>]. However, based on accumulating evidence, we favor including anaerobic coverage in treatment regimens for PID, including mild to moderate PID that is treated in the outpatient setting [<a href="#rid6">6</a>]. This approach is consistent with guidelines from the United States Centers for Disease Control and Prevention [<a href="#rid2">2</a>] and the European Sexually Transmitted Infections Guidelines Editorial Board [<a href="#rid7">7</a>]. (See <a class="local">'Antibiotic selection'</a> below and <a class="local">'Outpatient therapy'</a> below.)</p><p>Although several studies of females with PID have demonstrated the presence of anaerobes in the genital tract at initial presentation, several regimens without dedicated anaerobic coverage (eg, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) result in excellent clinical cure rates among females with mild to moderate PID [<a href="#rid5">5,8</a>]. However, there may be benefits to anaerobic coverage beyond short-term clinical response: </p><p class="bulletIndent1"><span class="glyph">●</span>In one trial of 233 females with mild to moderate PID who were randomly assigned to receive <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (single dose) and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> for 14 days with either <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg twice daily) or placebo for 14 days, clinical improvement rates at three days were similar in the two groups (82.8 versus 80.3 percent, respectively) [<a href="#rid6">6</a>]. However, at 30 days, females in the metronidazole group had a lower rate of pelvic tenderness (9 versus 20 percent); there was also a trend toward higher 30-day clinical cure rates with metronidazole (96 versus 90 percent), but this was not statistically significant. Females who received metronidazole were less likely to have bacterial vaginosis (21 versus 54 percent), and there was a nonsignificant trend toward fewer <em>T. vaginalis</em> infections as well (5 versus 12 percent). Metronidazole was also associated with lower rates of isolating anaerobic bacteria from endometrium at 30 days, although the clinical significance of this finding is uncertain.</p><p></p><p>There has been concern that the additional gastrointestinal side effects of anaerobic therapy (eg, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>) would result in nonadherence and inadequately treated PID. However, in the trial described above, rates of adherence were similar with regimens with and without metronidazole [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3716139577"><span class="h2">M. genitalium</span><span class="headingEndMark"> — </span><em>M. genitalium</em> infection has been associated with symptomatic PID. However, we do not suggest including targeted <em>M. genitalium</em> coverage in empiric PID regimens. Recommended treatment regimens are not highly effective against <em>M. genitalium</em>, yet clinical response rates are high. </p><p>There are no data on the benefits of screening and treating females with acute PID for <em>M. genitalium</em>, and there is no consensus on whether PID treatment regimens should include coverage for this organism. (See  <a class="medical medical_review" href="/z/d/html/83202.html" rel="external">"<i>Mycoplasma genitalium</i> infection"</a>.) </p><p class="headingAnchor" id="H2712604115"><span class="h1">THRESHOLD FOR TREATMENT</span><span class="headingEndMark"> — </span>Clinicians should maintain a low threshold of suspicion for the diagnosis and treatment of PID. The presumptive clinical diagnosis of PID is made in sexually active young women or women at risk for sexually transmitted infections (STIs) who present with pelvic or lower abdominal pain and have evidence of cervical motion, uterine, or adnexal tenderness on exam [<a href="#rid2">2</a>]. Occasionally, acute PID can occur in females without recent sexual activity. Treatment is indicated for patients with this presumptive clinical diagnosis of PID, even if findings are subtle or minimal, since the risk of long-term complications is higher if treatment is withheld or delayed [<a href="#rid1">1,2</a>]. </p><p>The evaluation and diagnosis of PID is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p>Evaluation for and diagnosis of tubo-ovarian abscess, a complication of PID, is also discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7589.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of tubo-ovarian abscess", section on 'Evaluation of patients with suspected TOA'</a>.)</p><p class="headingAnchor" id="H1024815"><span class="h1">INDICATIONS FOR HOSPITALIZATION</span><span class="headingEndMark"> — </span>Most females with PID can be safely treated in outpatient settings. Indications for hospitalization and parenteral antibiotics include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe clinical illness (eg, fever ≥38.5°C [101°F], nausea and vomiting)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complicated PID with pelvic abscess (including tubo-ovarian abscess) (see  <a class="medical medical_review" href="/z/d/html/7589.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of tubo-ovarian abscess", section on 'Diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Possible need for invasive diagnostic evaluation for alternate etiology (eg, appendicitis or ovarian torsion) or surgical intervention for suspected ruptured tubo-ovarian abscess </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to take oral medications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of response or tolerance to oral medications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concern for nonadherence to therapy</p><p></p><p>There has been a trend towards outpatient treatment of PID, with only the minority of females being hospitalized [<a href="#rid9">9,10</a>]. Support for outpatient therapy for mild or moderate PID comes from the Pelvic Inflammatory Disease Evaluation Clinical Health trial (ie, PEACH trial) [<a href="#rid11">11</a>]. In that trial, 831 females with lower abdominal pain, uterine or adnexal tenderness, and mucopurulent cervicitis or untreated gonococcal or chlamydial infection were randomly assigned to inpatient therapy with intravenous <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> for at least 48 hours plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or outpatient therapy with a single intramuscular dose of cefoxitin with <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> plus doxycycline. Short-term clinical and microbiologic outcomes and long-term reproductive outcomes (eg, ectopic pregnancy, chronic pelvic pain) were similar between the two groups. </p><p>There are no clinical data to suggest that older age or HIV infection should be considered criteria for hospitalization [<a href="#rid2">2,12</a>]. </p><p class="headingAnchor" id="H6"><span class="h1">ANTIBIOTIC SELECTION</span><span class="headingEndMark"> — </span>Antibiotic therapy is the cornerstone of pelvic inflammatory disease (PID) treatment. The therapeutic regimens for PID should provide broad empiric coverage for the wide array of implicated pathogens, although the optimal treatment regimen remains undefined [<a href="#rid13">13-16</a>]. Regimen options depend on whether the patient is initially hospitalized or managed as an outpatient, which generally depends on the severity of infection  (<a class="graphic graphic_algorithm graphicRef118249" href="/z/d/graphic/118249.html" rel="external">algorithm 1</a>) (see <a class="local">'Indications for hospitalization'</a> above). The selection of a regimen additionally takes into account cost, convenience of administration, safety, formulary availability, and allergy history. (See <a class="local">'Hospitalized patients'</a> below and <a class="local">'Outpatient therapy'</a> below.)</p><p>Meta-analyses have demonstrated that a variety of antibiotics from multiple classes are all associated with clinical and microbiologic cure rates of greater than 90 percent [<a href="#rid13">13,17,18</a>]. However, the available clinical data have limitations. Some studies did not use objective criteria to define PID, some have evaluated subjective pain outcomes without blinding of investigators, and few randomized trials have long-term data on outcomes, such as risk of infertility, ectopic pregnancy, and chronic pelvic pain following treatment. </p><p>Evaluation of regimen efficacy is also hampered by the inability to distinguish between relapse versus reinfection. As an example, the Pelvic Inflammation Disease Evaluation Clinical Health trial (ie, PEACH trial), which carefully assessed patients for <em>N. gonorrhoeae</em> and <em>C. trachomatis</em> infections, demonstrated that 40 percent of the females had evidence of at least one of these infections at baseline; by 30 days after treatment, approximately 3 percent still had evidence of either infection, but whether this reflected relapse (and thus treatment failure) or new infection is uncertain [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H1025616"><span class="h2">Hospitalized patients</span></p><p class="headingAnchor" id="H1025583"><span class="h3">Initial parenteral therapy</span><span class="headingEndMark"> — </span>Initial therapy consists of a combination parenteral regimen that provides antimicrobial coverage against a wide range of bacteria, including <em>C. trachomatis</em>, <em>N. gonorrhoeae</em>, streptococci, gram-negative enteric bacilli (<em>Escherichia coli</em>, <em>Klebsiella</em> spp, and <em>Proteus</em> spp), and anaerobic organisms (ie, bacterial vaginosis-associated flora)  (<a class="graphic graphic_algorithm graphicRef118249" href="/z/d/graphic/118249.html" rel="external">algorithm 1</a>). </p><p>We suggest one of the following regimens, which are consistent with first-line regimens recommended by the United States Centers for Disease Control and Prevention (CDC) [<a href="#rid2">2</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> (1 g intravenously every 24 hours) <strong>plus</strong> <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally or intravenously every 12 hours) <strong>plus </strong><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg orally or intravenously every 12 hours)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">Cefoxitin</a> (2 g intravenously every six hours) <strong>plus</strong> <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally or intravenously every 12 hours) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">Cefotetan</a> (2 g intravenously every 12 hours) <strong>plus</strong> <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally or intravenously every 12 hours)</p><p></p><p>Oral administration of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is generally preferred, if the patient can tolerate it, because of the pain associated with intravenous drug administration. The bioavailabilities of the oral and parenteral formulations are equivalent for both doxycycline and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>.</p><p>Combination regimens that include a cephalosporin and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> have been shown in several trials to result in short-term clinical cure rates of more than 80 to 90 percent of cases [<a href="#rid17">17,18</a>]. They have excellent in vitro activity against <em>N. gonorrhoeae</em> and <em>C. trachomatis</em> [<a href="#rid2">2,19</a>]. <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">Cefoxitin</a> and <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a> have intrinsic anaerobic activity; <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is added to the ceftriaxone-based regimen to provide anaerobic activity. (See <a class="local">'Anaerobic bacteria'</a> above.) </p><p>Alternative regimens have more limited clinical data to support their use for hospitalized patients or have other drawbacks. We do not routinely use them for patients with PID, but it is reasonable to use them in case of allergy to or unavailability of the preferred regimens:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (900 mg intravenously every eight hours) <strong>plus</strong> <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> (3 to 5 mg/kg intravenously daily or 2 mg/kg intravenously once followed by 1.5 mg/kg every eight hours). In a meta-analysis of 10 studies comparing a cephalosporin (usually in combination with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) with clindamycin plus gentamicin for severe PID, short-term clinical and microbiologic cure were similar with each regimen [<a href="#rid18">18</a>]. However, this regimen may be associated with a higher risk of toxicity than preferred regimens. In vitro activity against <em>N. gonorrhoeae</em> and <em>C. trachomatis</em> is moderate [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides", section on 'Gentamicin and tobramycin dosing in adults'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">Ampicillin-sulbactam</a> (3 g intravenously every six hours) plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily). This regimen has activity against <em>N. gonorrhoeae</em>, <em>C. trachomatis</em>, and anaerobes. Clinical data to support its use are limited. In one trial of 103 females hospitalized with PID, the regimen resulted in a similar clinical cure rate as <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> plus doxycycline regimen (86 versus 89 percent) [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">Azithromycin</a> (500 mg intravenously daily for one to two days followed by 250 mg orally daily to complete a seven-day course) plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg twice daily for 14 days). This dose of azithromycin, with or without metronidazole, resulted in similarly high clinical and microbiologic cure rates (&gt;95 percent) for mild to moderate PID compared with a combination beta-lactam and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> regimen [<a href="#rid21">21</a>]. However, the regimen has not been evaluated in patients with severe PID, and it should only be considered when <em>N. gonorrhoeae</em> infection has been excluded or is unlikely because it does not provide coverage against that pathogen. When using azithromycin for PID, we favor adding metronidazole for anaerobic coverage. (See <a class="local">'Anaerobic bacteria'</a> above.)</p><p></p><p class="headingAnchor" id="H2201045935"><span class="h3">Transition to oral therapy</span><span class="headingEndMark"> — </span>Patients can usually be transitioned from parenteral to oral therapy after 24 to 48 hours of sustained clinical improvement, as reflected by resolution of fever, nausea, vomiting, and severe abdominal pain, if initially present  (<a class="graphic graphic_algorithm graphicRef118249" href="/z/d/graphic/118249.html" rel="external">algorithm 1</a>) [<a href="#rid22">22</a>]. </p><p>Oral therapy consists of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice daily and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg twice daily to complete a 14-day course. This regimen is also appropriate for females whose PID was complicated by pelvic abscess and females with documented <em>Trichomonas vaginalis</em> infection or bacterial vaginosis because it provides coverage for anaerobic bacteria. (See <a class="local">'Anaerobic bacteria'</a> above.)</p><p>For those who cannot tolerate <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg for one to two days followed by 250 mg once daily to complete a 14-day course) is an alternative; for those who cannot tolerate <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> 450 mg orally every six hours is an alternative. (See <a class="local">'Anaerobic bacteria'</a> above.) </p><p>Additional management considerations, including other potential antibiotic regimens, for females with a tubo-ovarian abscess are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16419.html" rel="external">"Management and complications of tubo-ovarian abscess", section on 'Clinical approach'</a>.)</p><p class="headingAnchor" id="H413397"><span class="h2">Outpatient therapy</span><span class="headingEndMark"> — </span>For females with mild to moderate PID who can tolerate oral medications and are expected to reasonably adhere to therapy, we suggest the following regimen  (<a class="graphic graphic_algorithm graphicRef118249" href="/z/d/graphic/118249.html" rel="external">algorithm 1</a>) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A single intramuscular dose of a long-acting cephalosporin plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily for 14 days) plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg orally twice daily for 14 days)</p><p></p><p>The optimal choice of a cephalosporin is uncertain. We prefer <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (500 mg for individuals &lt;150 kg or 1 g for individuals ≥150 kg, intramuscularly in a single dose) to use in combination with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, as it is the recommended cephalosporin for coverage of gonorrhea. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on '"High" dose intramuscular (IM) ceftriaxone'</a>.) </p><p>Other appropriate cephalosporins to use with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> include <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> (2 g intramuscularly) with <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> (1 g orally), <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> (1 g intramuscularly), and ceftizoxime (1 g intramuscularly). Cephalosporin-based regimens result in clinical and microbiologic cure rates of approximately 90 percent or higher [<a href="#rid17">17,18</a>]. The approach to patients with allergies that potentially preclude cephalosporin administration is discussed elsewhere. (See <a class="local">'Penicillin-allergic patients'</a> below.) </p><p>We favor the routine addition of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for coverage of anaerobic organisms based on evidence of improved longer-term outcomes compared with regimens without anaerobic coverage. (See <a class="local">'Anaerobic bacteria'</a> above.)</p><p>An alternative to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (either 500 mg daily for one to two days then 250 mg orally for a 14-day course or 1 g once per week for two weeks), to be given with the single cephalosporin dose and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. Small clinical trials suggest clinical efficacy [<a href="#rid23">23</a>], although data on microbiologic cures are not available, and azithromycin results in lower microbiologic cure rates for <em>C. trachomatis</em> in some anatomic locations compared with doxycycline. (See  <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Doxycycline as preferred agent'</a>.)</p><p class="headingAnchor" id="H3688696274"><span class="h2">Directed therapy and duration</span><span class="headingEndMark"> — </span>The empirically chosen antibiotic regimen is generally continued for the duration of the course. The therapy should not be modified or cut short if <em>N. gonorrhoeae</em> or <em>C. trachomatis</em> is not identified in clinical specimens.</p><p>The optimal duration of therapy is unknown. We treat for a total of 14 days. Most studies have used this duration of therapy, and it is standard in other guidelines [<a href="#rid2">2,7</a>]. Shorter courses of therapy have not been explored, mainly related to concerns regarding eradication of <em>C. trachomatis</em> in the setting of upper tract disease [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2562044773"><span class="h1">ADJUNCTIVE CARE</span><span class="headingEndMark"> — </span>Patients who are hospitalized for severe or complicated pelvic inflammatory disease (PID) may also warrant volume repletion, particularly if nausea/vomiting prevents oral intake. Other supportive measures include antiemetic, analgesic, and antipyretic medications. </p><p>Surgical interventions are usually reserved for patients with tubo-ovarian abscesses that are associated with sepsis, are large, or do not improve with medical therapy. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16419.html" rel="external">"Management and complications of tubo-ovarian abscess", section on 'Clinical approach'</a>.)</p><p class="headingAnchor" id="H2037771041"><span class="h1">COUNSELING</span></p><p class="headingAnchor" id="H3809112123"><span class="h2">Medication adherence</span><span class="headingEndMark"> — </span>Compliance with a long course of oral antibiotics can be problematic [<a href="#rid24">24</a>]. Patients should be educated about the importance of medication adherence and clinical outcomes. </p><p class="headingAnchor" id="H192045887"><span class="h2">Sexual activity</span><span class="headingEndMark"> — </span>Females with pelvic inflammatory disease (PID) should be counseled to refrain from sexual activity until they have completed therapy, their symptoms have resolved, and sex partners have been evaluated and/or treated for potential sexually transmitted infections (STIs) (see <a class="local">'Management of sex partners'</a> below). Clinicians should also counsel patients regarding the route of acquisition for STIs and future safe sex practices. (See  <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections", section on 'Prevention counseling'</a> and  <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections", section on 'Male condom use'</a>.)</p><p class="headingAnchor" id="H3411785991"><span class="h2">Screening and prevention of STIs</span><span class="headingEndMark"> — </span>All patients diagnosed with acute PID should be screened for other important STIs, including HIV and syphilis. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p>They should also be evaluated for indications for vaccinations to prevent other STIs, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B vaccination for those who have no evidence of immunity to hepatitis B virus (eg, through vaccination history or serologic testing). (See  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human papillomavirus vaccination for those within the appropriate age range if they have not previously been vaccinated. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p></p><p class="headingAnchor" id="H2975165028"><span class="h2">Management of sex partners</span><span class="headingEndMark"> — </span>Male sex partners of females with PID should be examined and treated if they had sexual contact with the patient during the 60 days prior to the patient's onset of symptoms, regardless of the woman's STI test results. Evaluation and treatment of the sex partner is essential to decrease the risk of reinfection. Regimens should include antibiotics with activity against <em>N. gonorrhoeae</em> and <em>C. trachomatis</em>; these regimens are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Initial treatment of urogenital infection'</a>.)</p><p>Expedited partner therapy, in which treatment of sex partners is facilitated by prescribing antibiotics for the partner without direct evaluation, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Management of sexual partners'</a>.)</p><p class="headingAnchor" id="H1351217381"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Close follow-up is essential. If outpatient therapy is selected, it is important to see the patient within 48 to 72 hours to be certain that clinical improvement has occurred (eg, reduction in abdominal tenderness and reduction in cervical motion tenderness) [<a href="#rid25">25</a>]. </p><p>Those who have no clinical improvement after this period warrant further diagnostic evaluation for complications (eg, pelvic abscesses) or for alternate diagnoses. Patients initially treated as outpatients warrant hospitalization and parenteral therapy. For those who were already on parenteral therapy, the initial regimen should be evaluated to ensure that it provided appropriate coverage (eg, for <em>N. gonorrhoeae </em>and anaerobes), and it should be adjusted if not. (See <a class="local">'Initial parenteral therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis", section on 'Additional evaluation for diagnostic uncertainty'</a>.)</p><p>For females who had documented <em>C. trachomatis</em> or <em>N. gonorrhoeae</em> infection, additional follow-up, including retesting, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Patient follow-up'</a> and  <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Follow-up testing'</a>.)</p><p class="headingAnchor" id="H1594275872"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H413492"><span class="h2">Penicillin-allergic patients</span></p><p class="headingAnchor" id="H333182793"><span class="h3">Assess whether cephalosporin can be used</span><span class="headingEndMark"> — </span>For patients with penicillin allergies, our approach depends on the type and severity of the allergy and the risk for gonococcal infection. Most patients with a penicillin allergy can still receive a cephalosporin. </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a penicillin allergy that was mild and had no features of an IgE-mediated reaction (eg, a maculopapular or morbilliform rash without angioedema, respiratory symptoms, or hypotension) can receive a third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) normally  (<a class="graphic graphic_algorithm graphicRef112936" href="/z/d/graphic/112936.html" rel="external">algorithm 2</a>). If needed, they can receive a second-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> or <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a>) with a test dose procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a penicillin allergy that did have features of an IgE-mediated reaction (eg, anaphylaxis or angioedema) can receive a third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) with a test dose procedure  (<a class="graphic graphic_algorithm graphicRef112936" href="/z/d/graphic/112936.html" rel="external">algorithm 2</a>). </p><p></p><p>A test dose procedure consists of giving one-tenth of the full dose (either intramuscularly or intravenously) and observing the patient for 30 to 60 minutes. If no reaction develops, the remainder of the dose can be given with continued observation for another hour. (See  <a class="medical medical_review" href="/z/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Test dose procedure (graded challenge)'</a>.)</p><p>For patients who receive a cephalosporin for PID treatment, it should be administered with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. (See <a class="local">'Initial parenteral therapy'</a> above and <a class="local">'Outpatient therapy'</a> above.)</p><p>If the beta-lactam allergy precludes cephalosporin use (eg, Stevens-Johnson Syndrome), patients who warrant hospitalization can receive <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, as outlined above. (See <a class="local">'Hospitalized patients'</a> above.)</p><p>For outpatients who cannot use a cephalosporin, the management options depend on the risk for gonorrhea, as outlined below. </p><p class="headingAnchor" id="H153729885"><span class="h3">For outpatients who cannot receive cephalosporins</span><span class="headingEndMark"> — </span>For those who cannot use a cephalosporin, options for outpatient therapy are limited. The main outpatient alternative is a fluoroquinolone-containing regimen. However, while certain fluoroquinolones have activity against <em>C. trachomatis</em>, high rates of fluoroquinolone resistance among <em>N. gonorrhoeae</em> isolates limit the utility of such regimens for PID. Thus, the approach to empiric management in this setting depends on the risk for fluoroquinolone-resistant <em>N. gonorrhoeae</em> (information on the community prevalence of resistance may be obtained from the local department of public health):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk of resistant gonorrhea </strong>– For females with PID in a region where the prevalence of fluoroquinolone resistance in <em>N. gonorrhoeae</em> is ≥5 percent, we suggest hospitalization for treatment with <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (900 mg intravenously every 8 hours) plus <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> (3 to 5 mg/kg intravenously once daily) until clinical improvement, at which point the regimen can be transitioned to oral therapy. (See <a class="local">'Transition to oral therapy'</a> above.)</p><p></p><p class="bulletIndent1">If there are major barriers to intravenous antibiotics, other alternative regimens for gonorrhea can be substituted into the outpatient therapy regimens for PID (eg, <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> 240 mg intramuscularly once plus <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> 2 g orally once in addition to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>); however, there are no data to inform PID outcomes with these regimens. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Alternate regimens'</a>.)</p><p></p><p class="bulletIndent1">In such individuals, we submit cervical specimens for culture for <em>N. gonorrhoeae</em> and request that susceptibility testing be performed on any isolate. If the patient has persistent symptoms, an infectious diseases consultation should be obtained. If retreatment is appropriate, potential options include desensitization to a cephalosporin or alternative regimens based on susceptibility testing. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Monitoring for and managing treatment failure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk of resistant gonorrhea</strong> – For females who have a low risk of fluoroquinolone-resistant <em>N. gonorrhoeae</em> (ie, infection acquired in a region where the prevalence is &lt;5 percent, postmenopausal females who develop PID following uterine instrumentation), a fluoroquinolone-containing regimen can be used. This consists of either the combination of <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg orally once daily plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> 500 mg orally twice daily or monotherapy with <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg orally once daily; each regimen is given for 14 days. </p><p></p><p class="bulletIndent1">Prior to use of a fluoroquinolone-containing regimen, we submit cervical specimens for culture for <em>N. gonorrhoeae</em> and request that susceptibility testing be performed on any isolate. If testing confirms susceptibility to fluoroquinolones, the fluoroquinolone-containing regimen can be continued. If a fluoroquinolone-resistant isolate is identified, an infectious diseases consultation should be obtained. Potential treatment options include desensitization to a cephalosporin or alternative regimens based on susceptibility testing. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Monitoring for and managing treatment failure'</a>.)</p><p></p><p class="bulletIndent1">In the absence of resistance, fluoroquinolones are clinically effective against PID. In a meta-analysis of randomized trials, there was no evidence of a clear difference in clinical cure for PID of any severity with fluoroquinolones compared with cephalosporin-based regimens or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> plus an aminoglycoside, but the included trials were conducted prior to the increased prevalence of fluoroquinolone-resistant gonorrhea [<a href="#rid18">18</a>]. </p><p></p><p>In situations in which <em>N. gonorrhoeae</em> has been excluded (ie, known negative NAAT) and the patient cannot receive a cephalosporin or a fluoroquinolone, an alternative regimen is <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg orally daily for one to two days followed by 250 mg daily or 1 g orally once per week for two weeks) with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg orally twice daily) for a total of 14 days [<a href="#rid26">26</a>]. </p><p>Molecular tests that can identify mutations associated with fluoroquinolone resistance in <em>N. gonorrhoeae</em> can help streamline this approach by identifying individuals who have susceptible infection and could thus use a fluoroquinolone; however, these tests are not widely available. (See  <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Fluoroquinolones'</a>.)</p><p class="headingAnchor" id="H2835945801"><span class="h2">Females with IUDs</span><span class="headingEndMark"> — </span>Intrauterine devices (IUDs) do not appear to be associated with an increased risk of PID [<a href="#rid27">27</a>]. Removal of an IUD in a woman who develops PID is not necessary. However, she should be followed closely, as with all females with PID, and removal may be warranted if she does not clinically improve with antibiotic therapy. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications", section on 'Infection and/or pelvic inflammatory disease'</a>.) </p><p class="headingAnchor" id="H613631186"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>While it is quite rare to have PID during pregnancy, the infection can occur in the first 12 weeks of gestation before the mucus plug and decidua seal off the uterus from ascending bacteria [<a href="#rid28">28</a>]. As above, pregnancy is an indication for hospitalization and parenteral antibiotics for PID. We typically administer a second-generation cephalosporin (eg, intravenous <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> or <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a>, as in first-line therapies listed above) and <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> 1 gram orally once (instead of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>). (See <a class="local">'Initial parenteral therapy'</a> above.)</p><p class="headingAnchor" id="H410518988"><span class="h2">Patients with HIV</span><span class="headingEndMark"> — </span>Females with HIV appear to respond to therapy for PID as well as females without HIV [<a href="#rid12">12</a>]. Therefore, recommended antibiotic regimens for acute PID in patients with HIV are the same as those for the general population.</p><p class="headingAnchor" id="H3766712807"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H10206903"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17117.html" rel="external">"Patient education: Pelvic inflammatory disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment</strong> – The presumptive clinical diagnosis of pelvic inflammatory disease (PID) is made in sexually active young women or women at risk for sexually transmitted infections (STIs) who present with pelvic or lower abdominal pain and have evidence of cervical motion, uterine, or adnexal tenderness on exam. Treatment is indicated for patients with this presumptive clinical diagnosis of PID, even if findings are subtle or minimal, since the risk of long-term complications is higher if treatment is withheld or delayed. (See <a class="local">'Threshold for treatment'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted pathogens</strong> – Treatment of PID consists of broad antimicrobial coverage against the likely pathogens, including <em>Neisseria gonorrhoeae</em>, <em>Chlamydia trachomatis</em>, and the gram-negative and gram-positive organisms that comprise the cervical and vaginal flora, including anaerobic organisms. Although <em>Mycoplasma genitalium</em> is associated with PID, routine testing for or empiric therapy of that organism is not clearly necessary. (See <a class="local">'Microbiologic considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for hospitalization</strong> – These include (see <a class="local">'Indications for hospitalization'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe clinical illness (eg, high fever, nausea/vomiting preventing oral intake, severe abdominal pain)</p><p class="bulletIndent2"><span class="glyph">•</span>Suspected pelvic abscess</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy</p><p class="bulletIndent2"><span class="glyph">•</span>A possible alternative diagnosis that could warrant surgery (eg, appendicitis) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic regimens for hospitalized patients </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial parenteral therapy</strong> – For patients who are hospitalized for PID, we suggest initial therapy with a third- or second-generation parenteral cephalosporin plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>  (<a class="graphic graphic_algorithm graphicRef118249" href="/z/d/graphic/118249.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We also suggest inclusion of anaerobic coverage (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">Appropriate regimens include <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 g intravenously every 24 hours) plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg orally twice daily); <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a> (2 g intravenously every six hours) plus doxycycline; and <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a> (2 g intravenously every 12 hours) plus doxycycline. The doxycycline dose is 100 mg orally every 12 hours. Intravenous administration of doxycycline or metronidazole is usually unnecessary. (See <a class="local">'Initial parenteral therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transition to oral antibiotics</strong> – The parenteral regimen can be transitioned to oral therapy after 24 to 48 hours of sustained clinical improvement. We suggest <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> 100 mg twice daily plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg orally twice daily) to complete a 14-day course (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Transition to oral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic regimens for outpatients</strong> – For patients with mild or moderate PID who are treated as outpatients, we suggest <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> as a single intramuscular dose (500 mg, or 1 g for individuals ≥150 kg) plus <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily for 14 days) plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (500 mg twice daily for 14 days) rather than other regimens  (<a class="graphic graphic_algorithm graphicRef118249" href="/z/d/graphic/118249.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This regimen provides coverage for <em>C. trachomatis</em>, <em>N. gonorrhoeae, </em>and anaerobic bacteria. (See <a class="local">'Outpatient therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to penicillin allergies</strong> – Most penicillin allergies do not prelude cephalosporin use. In such cases, the same regimens as recommended for those without allergies can be used. For patients who cannot use a cephalosporin, our approach depends on their risk of fluoroquinolone-resistant <em>N. gonorrhoeae</em>. (See <a class="local">'Penicillin-allergic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling </strong>– Patients should be counseled on the importance of medication adherence, refraining from sexual activity until treatment completion and symptom resolution, safe sex practices, and screening and prevention of other STIs. Male sexual contacts within the 60 days prior to the patient's onset of symptoms should be examined and/or treated to decrease the risk of reinfection. (See <a class="local">'Counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up </strong>– Close follow-up is essential. Patients receiving outpatient therapy should be evaluated for clinical improvement within 72 hours. Those who have not improved warrant hospitalization, parenteral therapy, and further workup. (See <a class="local">'Follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Soper DE. Pelvic inflammatory disease. Obstet Gynecol 2010; 116:419.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Taylor BD, Darville T, Haggerty CL. Does bacterial vaginosis cause pelvic inflammatory disease? Sex Transm Dis 2013; 40:117.</a></li><li><a class="nounderline abstract_t">Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect 2016; 92:441.</a></li><li><a class="nounderline abstract_t">Walker CK, Workowski KA, Washington AE, et al. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. Clin Infect Dis 1999; 28 Suppl 1:S29.</a></li><li><a class="nounderline abstract_t">Wiesenfeld HC, Meyn LA, Darville T, et al. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease. Clin Infect Dis 2021; 72:1181.</a></li><li><a class="nounderline abstract_t">Ross J, Guaschino S, Cusini M, Jensen J. 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 2018; 29:108.</a></li><li><a class="nounderline abstract_t">Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24:170.</a></li><li><a class="nounderline abstract_t">Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95:397.</a></li><li><a class="nounderline abstract_t">Bohm MK, Newman L, Satterwhite CL, et al. Pelvic inflammatory disease among privately insured women, United States, 2001-2005. Sex Transm Dis 2010; 37:131.</a></li><li><a class="nounderline abstract_t">Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186:929.</a></li><li><a class="nounderline abstract_t">Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000; 95:525.</a></li><li><a class="nounderline abstract_t">Dodson MG. Antibiotic regimens for treating acute pelvic inflammatory disease. An evaluation. J Reprod Med 1994; 39:285.</a></li><li><a class="nounderline abstract_t">Landers DV, Wolner-Hanssen P, Paavonen J, et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. Am J Obstet Gynecol 1991; 164:849.</a></li><li><a class="nounderline abstract_t">Wasserheit JN, Bell TA, Kiviat NB, et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Intern Med 1986; 104:187.</a></li><li><a class="nounderline abstract_t">Brunham RC, Binns B, Guijon F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis 1988; 158:510.</a></li><li><a class="nounderline abstract_t">Walker CK, Kahn JG, Washington AE, et al. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis 1993; 168:969.</a></li><li><a class="nounderline abstract_t">Savaris RF, Fuhrich DG, Maissiat J, et al. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst Rev 2020; 8:CD010285.</a></li><li><a class="nounderline abstract_t">Hemsell DL, Little BB, Faro S, et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clin Infect Dis 1994; 19:720.</a></li><li><a class="nounderline abstract_t">McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994; 83:998.</a></li><li><a class="nounderline abstract_t">Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31:45.</a></li><li><a class="nounderline abstract_t">Livengood CH 3rd, Hill GB, Addison WA. Pelvic inflammatory disease: findings during inpatient treatment of clinically severe, laparoscopy-documented disease. Am J Obstet Gynecol 1992; 166:519.</a></li><li><a class="nounderline abstract_t">Savaris RF, Teixeira LM, Torres TG, et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol 2007; 110:53.</a></li><li><a class="nounderline abstract_t">Brookoff D. Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease. South Med J 1994; 87:1088.</a></li><li><a class="nounderline abstract_t">Thompson SE, Brooks C, Eschenbach DA, et al. High failure rates in outpatient treatment of salpingitis with either tetracycline alone or penicillin/ampicillin combination. Am J Obstet Gynecol 1985; 152:635.</a></li><li><a class="nounderline abstract_t">Judlin P, Liao Q, Liu Z, et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117:1475.</a></li><li><a class="nounderline abstract_t">Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356:1013.</a></li><li><a class="nounderline abstract_t">Zeger W, Holt K. Gynecologic infections. Emerg Med Clin North Am 2003; 21:631.</a></li></ol></div><div id="topicVersionRevision">Topic 7585 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664404" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324974" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Does bacterial vaginosis cause pelvic inflammatory disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26825087" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Identification of novel microbes associated with pelvic inflammatory disease and infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028108" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32052831" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29198181" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2017 European guideline for the management of pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114143" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711551" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051931" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pelvic inflammatory disease among privately insured women, United States, 2001-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015517" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10725484" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influence of human immunodeficiency virus infection on pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040846" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibiotic regimens for treating acute pelvic inflammatory disease. An evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900663" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3004276" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3045213" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Etiology and outcome of acute pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8376843" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32820536" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antibiotic therapy for pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7803638" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190448" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12635534" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531573" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pelvic inflammatory disease: findings during inpatient treatment of clinically severe, laparoscopy-documented disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601896" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973890" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3895937" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : High failure rates in outpatient treatment of salpingitis with either tetracycline alone or penicillin/ampicillin combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20716255" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041414" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intrauterine device and upper-genital-tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12962350" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gynecologic infections.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
